We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.50 | 19.72% | 21.25 | 20.50 | 22.00 | 23.50 | 18.50 | 18.50 | 10,311,990 | 16:17:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -2.55 | 55.37M |
TIDMAGL
RNS Number : 3493D
Angle PLC
09 October 2018
For immediate release 9 October 2018
ANGLE plc ("the Company")
Notice of AGM and Posting of Annual Report and Accounts
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that its AGM will be held at 2:00 pm on Tuesday 30 October 2018 at ANGLE plc, 10 Nugent Road, the Surrey Research Park, Guildford, GU2 7AF.
The Annual Report and Accounts for the year ended 30 April 2018, posted to shareholders on 8 October 2018, together with the Notice of the Company's Annual General Meeting ("AGM") are available for download on the Company's website, www.angleplc.com.
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director finnCap Ltd (NOMAD and Joint Broker) Corporate Finance - Carl Holmes, Simon Hicks, Max Bullen-Smith ECM - Alice Lane +44 (0)20 7220 0500 WG Partners (Joint Broker) Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee +44 (0) 203 705 9330 FTI Consulting Simon Conway, Mo Noonan, Stephanie Cuthbert +44 (0) 203 727 1000 Matthew Ventimiglia (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to answer solutions. ANGLE's proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM) system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. The Parsortix system has a CE Mark for Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of all types is called Ziplex(R) and is based on a patented flow through array technology. It provides for highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. These technologies can be combined to provide fully automated, sample to answer results in both centralised laboratory and point of use cartridge formats. It is ideal for measuring gene expression and other markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NOAFKFDNCBDDCKK
(END) Dow Jones Newswires
October 09, 2018 02:00 ET (06:00 GMT)
1 Year Angle Chart |
1 Month Angle Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions